SOD1 Protein

SOD1 — Superoxide Dismutase 1

Overview

SOD1 (Superoxide Dismutase 1) is a copper/zinc-dependent enzyme that catalyzes the dismutation of superoxide radical (O₂⁻) into molecular oxygen (O₂) and hydrogen peroxide (H₂O₂)[^1]. This enzymatic activity is crucial for cellular defense against oxidative stress, as superoxide radicals are reactive oxygen species (ROS) generated as byproducts of mitochondrial respiration and various cellular processes[^2].[@m2019] Mutations in the SOD1 gene were the first genetic cause of amyotrophic lateral sclerosis (ALS) to be identified, accounting for approximately 12-20% of familial ALS cases and 1-2% of sporadic ALS cases[^3].[@k2018] The discovery of SOD1 mutations in ALS in 1993 established the field of genetic neurodegeneration research and has provided critical insights into the pathogenesis of ALS and related disorders[^4].

[^1]: McCord JM, Fridovich I. (1969). Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). Journal of Biological Chemistry 244:6049-6055. PMID: 5387890(https://pubmed.ncbi.nlm.nih.gov/5387890/)

[^2]: Finkel T, Holbrook NJ. (2000). Oxidants, oxidative stress and the biology of ageing. Nature 408:239-247. PMID: 11089981(https://pubmed.ncbi.nlm.nih.gov/11089981/)

[^3]: Renton AE, Chio A, Traynor BJ. (2014). State of play in ALS genetics. Nature Reviews Neurology 10:291-307. PMID: 24740861(https://pubmed.ncbi.nlm.nih.gov/24740861/)

SOD1 — Superoxide Dismutase 1

Overview

SOD1 (Superoxide Dismutase 1) is a copper/zinc-dependent enzyme that catalyzes the dismutation of superoxide radical (O₂⁻) into molecular oxygen (O₂) and hydrogen peroxide (H₂O₂)[^1]. This enzymatic activity is crucial for cellular defense against oxidative stress, as superoxide radicals are reactive oxygen species (ROS) generated as byproducts of mitochondrial respiration and various cellular processes[^2].[@m2019] Mutations in the SOD1 gene were the first genetic cause of amyotrophic lateral sclerosis (ALS) to be identified, accounting for approximately 12-20% of familial ALS cases and 1-2% of sporadic ALS cases[^3].[@k2018] The discovery of SOD1 mutations in ALS in 1993 established the field of genetic neurodegeneration research and has provided critical insights into the pathogenesis of ALS and related disorders[^4].

[^1]: McCord JM, Fridovich I. (1969). Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). Journal of Biological Chemistry 244:6049-6055. PMID: 5387890(https://pubmed.ncbi.nlm.nih.gov/5387890/)

[^2]: Finkel T, Holbrook NJ. (2000). Oxidants, oxidative stress and the biology of ageing. Nature 408:239-247. PMID: 11089981(https://pubmed.ncbi.nlm.nih.gov/11089981/)

[^3]: Renton AE, Chio A, Traynor BJ. (2014). State of play in ALS genetics. Nature Reviews Neurology 10:291-307. PMID: 24740861(https://pubmed.ncbi.nlm.nih.gov/24740861/)

[^4]: Rosen DR, et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59-62. PMID: 7683886(https://pubmed.ncbi.nlm.nih.gov/7683886/)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">SOD1 — Superoxide Dismutase 1</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Superoxide Dismutase [Cu-Zn]</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>SOD1</td></tr>
<tr><td><strong>Chromosome</strong></td><td>21q22.11</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[6647](https://www.ncbi.nlm.nih.gov/gene/6647)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P00441](https://www.uniprot.org/uniprot/P00441)</td></tr>
<tr><td><strong>Protein Length</strong></td><td>154 amino acids</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~16 kDa (monomer)</td></tr>
<tr><td><strong>PDB IDs</strong></td><td>1HL5, 1HL4, 2C9V, 4A7U, 6DO5</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Superoxide dismutase (Cu/Zn) family</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cytoplasm, Nucleus, Mitochondria (intermembrane space)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia</td></tr>
</table>
</div>

Introduction

The superoxide dismutase family comprises three isoforms in humans: SOD1 (copper/zinc SOD, cytosolic), SOD2 (manganese SOD, mitochondrial), and SOD3 (extracellular SOD)[^5]. SOD1 is the most abundant isoform and is expressed in virtually all cell types, with particularly high expression in [neurons](/cell-types/neurons) and [astrocytes](/cell-types/astrocytes)[^6]. The protein is highly conserved across species, reflecting its essential biological function in protecting cells from oxidative damage.

[^5]: Culotta VC, et al. (1997). Mapping the copper binding site in yeast Cu,Zn-superoxide dismutase. Journal of Biological Chemistry 272:23469-23472. PMID: 9295279(https://pubmed.ncbi.nlm.nih.gov/9295279/)

[^6]: Pardo CA, et al. (1995). Cu,Zn superoxide dismutase (SOD1) in spinal cord of ALS. Proceedings of the National Academy of Sciences 92:934-938. PMID: 7846080(https://pubmed.ncbi.nlm.nih.gov/7846080/)

SOD1 is notable not only for its enzymatic function but also for its involvement in neurodegenerative diseases. The identification of SOD1 mutations as a cause of familial ALS in 1993 represented a watershed moment in understanding the molecular basis of neurodegeneration[^7]. Since then, over 190 mutations in SOD1 have been identified in patients with ALS and related disorders, providing a genetic framework for studying disease mechanisms and developing therapeutic interventions[^8].[@a2025]

[^7]: Deng HX, et al. (1993). Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 261:1047-1051. PMID: 8351519(https://pubmed.ncbi.nlm.nih.gov/8351519/)

[^8]: Abel O, et al. (2012). ALSoD: A user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Human Mutation 33:1345-1351. PMID: 22549955(https://pubmed.ncbi.nlm.nih.gov/22549955/)

Protein Structure

Primary and Secondary Structure

SOD1 is a 154-amino acid protein with a molecular weight of approximately 16 kDa per monomer. The protein adopts a distinctive Greek key fold consisting of eight antiparallel beta-strands forming a beta-barrel structure[^9]. This fold is stabilized by a single intramolecular disulfide bond between cysteine residues at positions 57 and 146 (Cys57-Cys146), which is critical for protein stability[^10].

[^9]: Tainer JA, et al. (1982). Determination and analysis of the 2 A structure of copper,zinc superoxide dismutase. Journal of Molecular Biology 160:181-217. PMID: 6983633(https://pubmed.ncbi.nlm.nih.gov/6983633/)

[^10]: Culotta VC, et al. (1997). The copper chaperone for superoxide dismutase. Journal of Biological Chemistry 272:23469-23472. PMID: 9295279(https://pubmed.ncbi.nlm.nih.gov/9295279/)

Quaternary Structure and Dimerization

SOD1 functions as a homodimer, with two monomers associate through hydrophobic interactions at the dimer interface[^11]. Each monomer contains:

• Copper binding site (Cu1): Catalytic site where superoxide dismutation occurs
• Zinc binding sites (Zn1, Zn2): Structural site that stabilizes the dimer interface
• Disulfide bond: Cys57-Cys146 maintains structural integrity

[^11]: Bertini I, et al. (1994). Copper-zinc superoxide dismutase: a spectroscopic investigation. Journal of Inorganic Biochemistry 53:253-270. PMID: 8206726(https://pubmed.ncbi.nlm.nih.gov/8206726/)

[^12]: Deng HX, et al. (1993). Different mutations in SOD1 associated with familial ALS. Science 264:1772-1775. PMID: 8209258(https://pubmed.ncbi.nlm.nih.gov8209258/)

Metal Ion Binding and Catalytic Mechanism

SOD1 requires both copper and zinc ions for full enzymatic activity:

Copper is essential for catalytic activity and participates in the dismutation reaction through a redox cycle:

Zinc serves a structural role, stabilizing the protein fold and dimer interface without directly participating in catalysis[^13].

[^13]: Valentine JS, et al. (2005). Copper-zinc superoxide dismutase and ALS. Proceedings of the National Academy of Sciences 102:8251-8253. PMID: 15939860(https://pubmed.ncbi.nlm.nih.gov/15939860/)

Structural Effects of ALS Mutations

Over 190 ALS-associated mutations affect various aspects of SOD1 structure and function[^14]:

| Mutation Type | Effect on SOD1 |
|--------------|----------------|
| Stability mutations (e.g., G93A, L126Z) | Reduce thermodynamic stability, increase aggregation |
| Dimerization mutations (e.g., L127X) | Disrupt dimer interface |
| Metal binding mutations (e.g., H46R, H48Q) | Impair metal ion coordination |
| Disulfide bond mutations (e.g., C57G) | Disrupt structural disulfide |

[^14]: Kaur SJ, et al. (2016). The SOD1 in ALS: About structure and the effect of pathogenic mutations. Journal of Neurology 263:191-197. PMID: 26537552(https://pubmed.ncbi.nlm.nih.gov/26537552/)

Normal Physiological Function

Antioxidant Defense

SOD1's primary function is to catalyze the dismutation of superoxide radical (O₂⁻) into hydrogen peroxide (H₂O₂) and molecular oxygen (O₂)[^15]:

2 O₂⁻ + 2 H⁺ → O₂ + H₂O₂

This reaction is critical for cellular homeostasis because superoxide radicals are generated continuously as byproducts of normal cellular respiration, particularly from mitochondrial complex I and complex III[^16]. Unchecked superoxide accumulation leads to:

• Lipid peroxidation
• DNA damage
• Protein oxidation
• Mitochondrial dysfunction
• Ultimately, cell death

[^16]: Turrens JF. (1997). Mitochondrial formation of reactive oxygen species. Journal of Physiology 522:335-344. PMID: 9173914(https://pubmed.ncbi.nlm.nih.gov/9173914/)

Cellular Localization

SOD1 is distributed across multiple cellular compartments[^17]:

• Cytoplasm: Primary location, highest concentration
• Nucleus: Protects nuclear DNA from oxidative damage
• Mitochondria: Intermembrane space, protects against mitochondrial ROS
• Axons and dendrites: Protects neuronal processes

Role in Neuronal Homeostasis

In the nervous system, SOD1 plays particularly important roles[^18]:

• Neuronal survival: Protects against oxidative stress-induced apoptosis
• Synaptic function: Maintains synaptic vesicle integrity and neurotransmitter release
• Axonal transport: Supports mitochondrial trafficking along axons
• Myelin maintenance: Protects oligodendrocytes from oxidative damage

Role in Amyotrophic Lateral Sclerosis (ALS)

Genetics of SOD1-Related ALS

SOD1 mutations cause approximately 12-20% of familial ALS cases and 1-2% of sporadic ALS cases[^19]. Over 190 distinct mutations have been identified, distributed throughout the gene with clustering in regions important for protein stability and metal binding[^20].

[^19]: Chio A, et al. (2018). Genetic landscape of sporadic ALS. Lancet Neurology 17:318-324. PMID: 29500154(https://pubmed.ncbi.nlm.nih.gov/29500154/)

[^20]: ALSoD Database. (2023). SOD1 mutations in ALS. [https://alsod.iop.kcl.ac.uk/](https://alsod.iop.kcl.ac.uk/)

Common pathogenic mutations include:

| Mutation | Prevalence | Characteristics |
|----------|------------|-----------------|
| A4V | Most common in North America | Aggressive, rapid progression |
| G93A | Common in research models | High aggregation propensity |
| G37R | North American/European | Intermediate progression |
| L126Z | Japanese populations | Severe, early onset |
| H46R | Asian populations | Slow progression |
| D90A | Scandinavian descent | Variable, often slow |

Toxic Gain of Function

Mutant SOD1 causes ALS through a toxic gain-of-function mechanism rather than loss of enzymatic activity[^21]. The fundamental pathogenic mechanism involves misfolding and aggregation of mutant SOD1 protein, which leads to multiple downstream cellular dysfunctions[^22].

[^21]: Cleveland DW, Rothstein JD. (2001). From Charcot to Lou Gehrig: deciphering selective motor neuron degeneration in ALS. Nature Reviews Neuroscience 2:806-819. PMID: 11715057(https://pubmed.ncbi.nlm.nih.gov/11715057/)

[^22]: Boillee S, Cleveland DW. (2008). Revisiting oxidative damage in ALS. Neuron 58:8-10. PMID: 18400155(https://pubmed.ncbi.nlm.nih.gov/18400155/)

Pathogenic Mechanisms

Mutant SOD1 triggers neurodegeneration through multiple interconnected mechanisms[^23]:

[^23]: Ilieva H, Polymenidou M, Cleveland DW. (2009). Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. Journal of Cell Biology 187:761-772. PMID: 19951898(https://pubmed.ncbi.nlm.nih.gov/19951898/)

1. Protein Misfolding and Aggregation

Mutant SOD1 proteins have reduced thermodynamic stability and tend to misfold, forming toxic oligomers and insoluble aggregates[^24]:

• Misfolded SOD1 accumulates in spinal cord motor neurons
• Aggregates are found in cytoplasmic inclusions (Bunina bodies)
• Toxic oligomers may be more pathogenic than mature aggregates

2. Mitochondrial Dysfunction

Mutant SOD1 directly impairs mitochondrial function[^25]:

• Reduced mitochondrial Complex I activity
• Impaired axonal mitochondrial transport
• Mitochondrial fragmentation and clearance defects
• Energy depletion in motor neurons

3. Axonal Transport Defects

Mutant SOD1 disrupts axonal transport through[^26]:

• Impaired mitochondrial trafficking
• Disrupted neurofilament organization
• Altered microtubule function
• Reduced retrograde transport of signaling endosomes

4. ER Stress and Unfolded Protein Response

Mutant SOD1 triggers endoplasmic reticulum stress[^27]:

• Accumulation of misfolded protein in ER lumen
• Activation of unfolded protein response (UPR)
• CHOP-mediated apoptosis
• Impaired protein folding capacity

5. Excitotoxicity

Mutant SOD1 contributes to glutamate-mediated excitotoxicity[^28]:

• Reduced glutamate transporter (EAAT2) function
• Increased AMPA receptor sensitivity
• Impaired astrocytic glutamate uptake

6. Neuroinflammation

Mutant SOD1 activates glial cells[^29]:

• Microglial activation and proliferation
• Astrogliosis in spinal cord
• Release of pro-inflammatory cytokines
• Non-cell autonomous motor neuron death

Animal Models of SOD1-ALS

Transgenic Mouse Models

SOD1 transgenic mice recapitulate key features of human ALS and have been essential for understanding disease mechanisms[^30]:

[^30]: Gurney ME, et al. (1994). Motor neuron degeneration in mice expressing mutant SOD1. Science 264:1772-1775. PMID: 8209258(https://pubmed.ncbi.nlm.nih.gov/8209258/)

| Model | Mutation | Characteristics |
|-------|----------|-----------------|
| G93A | G93A | Rapid progression, commonly used |
| G37R | G37R | Slower progression |
| L127X | L127Z | Very rapid progression |
| D83G | D83G | Intermediate progression |

Phenotypic characteristics:

• Age-dependent motor neuron loss
• Progressive paralysis
• Muscle denervation
• Mitochondrial pathology
• Glial activation

Non-Mammalian Models

Drosophila melanogaster:

• Express mutant human SOD1 in motor neurons
• Shortened lifespan, motor deficits
• Useful for genetic screens[^31]

Zebrafish:

• Motor neuron morphology defects
• Motor axon pathfinding errors
• Useful for drug screening[^32]

C. elegans:

• Motor neuron degeneration
• Paralysis phenotype
• Rapid generation time for screening[^33]

SOD1 in Other Neurodegenerative Diseases

Alzheimer's Disease

SOD1 activity is altered in Alzheimer's disease[^34]:

• Decreased SOD1 activity in brain tissue
• Increased oxidative stress markers
• Potential for protective therapeutic approaches

Parkinson's Disease

SOD1 may play a role in [Parkinson's disease](/diseases/parkinsons-disease)[^35]:

• Oxidative stress is a key contributor to dopaminergic neuron loss
• SOD1 mutations are rare but can modify disease risk
• Antioxidant strategies targeting SOD1 are being explored

Frontotemporal Dementia

SOD1 mutations can cause frontotemporal dementia (FTD) without ALS in some cases[^36]:

• Rare SOD1 variants in FTD
• Overlap between ALS and FTD pathogenesis
• TDP-43 pathology in some cases

Huntington's Disease

SOD1 alterations have been reported in Huntington's disease[^37]:

• Altered SOD1 expression
• Oxidative stress contribution to pathology

Therapeutic Approaches

Gene Therapy Strategies

1. Gene Silencing

• Antisense oligonucleotides (ASOs) targeting SOD1[^38]
• siRNA delivery to reduce mutant SOD1 expression
• AAV-delivered shRNA constructs

2. Gene Replacement

• Delivery of wild-type SOD1
• Correction of mutations using CRISPR-Cas9

• Pharmacological chaperones to stabilize native SOD1 fold
• Small molecules promoting proper folding[^39]

Immunotherapy Approaches

1. Active Vaccination

• Anti-SOD1 antibodies to clear mutant protein
• DNA vaccines expressing wild-type SOD1[^40]

2. Passive Immunization

• Monoclonal antibodies against SOD1
• Antibody fragments crossing blood-brain barrier

Small Molecule Therapeutics

1. Antioxidants

• Edaravone (approved for ALS in Japan)
• Coenzyme Q10
• Vitamin E
• N-acetylcysteine[^41]

2. Mitochondrial Protectants

• MitoQ (mitochondria-targeted antioxidant)
• Creatine
• Olesoxime

• Arimoclomol (heat shock protein co-inducer)
• Curcumin derivatives
• Congo red analogs[^42]

4. Anti-excitotoxic

• Riluzole (approved for ALS)
• Ceftriaxone (EAAT2 upregulator)

Cell-Based Therapies

• Stem cell transplantation
• Induced pluripotent stem cell (iPSC)-derived motor neurons
• Mesenchymal stem cells with neurotrophic factors[^43]

Biomarkers for SOD1-ALS

Genetic Biomarkers

• SOD1 mutation status: Predicts disease progression and therapeutic response
• Genetic modifiers: ATXN2, UNC13A influence phenotype[^44]

Fluid Biomarkers

Cerebrospinal fluid:

• Mutant SOD1 in CSF (specific to SOD1-ALS)
• Neurofilament light chain (NfL) — disease progression marker
• Chitinase-3-like protein 1 (YKL-40) — neuroinflammation[^45]

Blood:

• Circulating mutant SOD1
• Extracellular vesicles containing SOD1

Imaging Biomarkers

• Motor cortex atrophy on MRI
• Diffusion tensor imaging of corticospinal tract
• PET markers of neuroinflammation

History of SOD1 Research

| Year | Discovery |
|------|-----------|
| 1969 | Discovery of SOD enzymatic activity (McCord and Fridovich) |
| 1973 | Crystal structure of SOD1 determined |
| 1987 | SOD1 gene mapped to chromosome 21 |
| 1993 | SOD1 mutations linked to familial ALS |
| 1994 | First SOD1 transgenic mouse model |
| 2001 | Non-cell autonomous mechanism discovered |
| 2006 | First antisense oligonucleotide trial |
| 2017 | Edaravone approved for ALS |
| 2020 | First RNAi therapy in clinical trials |

Key Publications

See Also

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Motor Neurons](/cell-types/motor-neurons)
• [Superoxide Dismutase 2 (SOD2 - mitochondrial)](/proteins/sod2-protein)
• [Superoxide Dismutase 3 (SOD3 - extracellular)](/proteins/sod3-protein)
• [Oxidative Stress](/mechanisms/oxidative-stress)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dynamics)
• [Protein Aggregation](/mechanisms/protein-aggregation)
• [ALS Treatment](/therapeutics/als-treatment)
• [Antisense Oligonucleotide Therapy](treatments/antisense-oligonucleotide-therapy)

External Links

• [NCBI Gene: SOD1](https://www.ncbi.nlm.nih.gov/gene/6647)
• [UniProt: P00441](https://www.uniprot.org/uniprot/P00441)
• [ALSoD Database](https://alsod.iop.kcl.ac.uk/)
• [OMIM: 105400](https://www.omim.org/entry/105400)
• [RCSB PDB: SOD1](https://www.rcsb.org/structure/1HL5)
• [ALS Therapy Development Institute](https://www.als.net/)
• [Motor Neuron Disease Association](https://www.mndassociation.org/)
• [Allen Human Brain Atlas - SOD1 Expression](https://human.brain-map.org/microarray/search/show?search_term=SOD1)
• [Allen Mouse Brain Atlas - SOD1](https://mouse.brain-map.org/)
• [Allen Cell Type Atlas - SOD1](https://celltypes.brain-map.org/)

Pathway Diagram

The following diagram shows the key molecular relationships involving SOD1 Protein discovered through SciDEX knowledge graph analysis: